How Mounjaro targets fat loss — and what actually happens in your body

Step 1: what tirzepatide does the moment it enters your system

Mounjaro belongs to a class called dual GIP and GLP-1 receptor agonists. Those two receptors sit on cells throughout the gut, brain and pancreas, and both have a role in telling the body how hungry it is and how quickly to process a meal. When tirzepatide activates them simultaneously, the result is a stronger appetite-suppressing effect than stimulating either receptor alone. Gastric emptying slows, food stays in the stomach longer, which extends the sense of fullness after a meal. At the same time, the brain receives signals that reduce the pull towards high-calorie foods. The net effect, over weeks, is that most people eat considerably less without the white-knuckle effort of deliberate restriction.

It is worth being clear that tirzepatide does not selectively target fat stores in the way a fat-burning supplement might claim. Weight comes off because energy intake falls below energy expenditure. The biology, though, makes that deficit far easier to sustain than diet alone, which is exactly what the trial data show.

For a fuller look at tirzepatide as a medicine, our tirzepatide overview covers the mechanism in more depth.

Step 2: the dose schedule and why it matters for fat loss

Treatment begins at 2.5mg, a dose whose job is to settle the digestive system, not to drive weight loss. Most people notice only modest appetite changes at this stage. The prescriber then increases the dose roughly every four weeks: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and finally 15mg if tolerated. The therapeutic fat-loss effect builds gradually as the dose rises. This is deliberate: the slow climb keeps nausea manageable and makes people far more likely to stay on treatment long enough to see meaningful results.

In practice, that titration plays out over several months. By the time someone reaches their maintenance dose they have usually already lost noticeable weight, though the steepest reduction tends to come in the middle phase of treatment when the dose is in the 7.5–12.5mg range. The SURMOUNT-1 data, published in the NEJM, show the dose-response clearly: average weight loss at 5mg was around 16%, rising to roughly 20–21% at 15mg over 72 weeks.

Practical note: the prescriber, not the pen schedule, decides when your dose increases. Titration is a clinical decision based on your tolerability and progress, something to discuss at each review, not a calendar you manage yourself.

Step 3: who the fat-loss licence actually covers

Mounjaro is licensed for weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or type 2 diabetes. NICE's appraisal of tirzepatide (TA1026) recommends it on the NHS for a narrower group (BMI 35 or above plus at least one qualifying condition) with thresholds 2.5 kg/m² lower for adults of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds.

Private prescribing follows the licensed criteria rather than the NICE NHS thresholds, so a broader group qualifies. BMI alone does not guarantee approval, though. A prescriber weighs up your full medical picture (existing conditions, current medicines, relevant history) before deciding tirzepatide is appropriate. Under-18s fall outside the licensed age range, and treatment is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive.

If you are curious how Mounjaro compares to other routes for fat loss, our Mounjaro weight loss guide covers the broader context. Questions about what to expect from treatment with an injection specifically are addressed on the fat jab Mounjaro page.

Step 4: side effects to understand before you start

The most common side effects are gastrointestinal: nausea, loose stools, constipation, indigestion and occasional vomiting. They tend to be most noticeable in the days after a dose increase and ease as the body adapts. Eating smaller, blander meals during those days helps. Fatigue and mild headache are also reported, particularly early on.

More serious effects are infrequent but matter to know about. The MHRA has highlighted acute pancreatitis as a known risk with GLP-1 medicines: severe, persistent stomach pain (sometimes spreading to the back) is a reason to stop treatment and get medical help promptly. Gallbladder problems, including gallstones, are also reported at higher rates than placebo in trial data. Any unusual symptoms should prompt a call to your prescriber or, if severe, 111 or A&E.

Some patients also ask whether tirzepatide affects mood. There are questions in the literature about GLP-1 medicines and emotional changes, our page on Mounjaro and mood covers what is and is not known. Side effects should be reported using the MHRA Yellow Card scheme, that data helps regulators track emerging signals in real-world use. One thing patients tell us they wish they had known: the first two weeks are often the hardest; if nausea settles, most people find it very manageable beyond that point.

Thinking about fat loss more broadly, or wondering how Mounjaro and tirzepatide can affect facial fat as weight comes off? Our weight-loss treatment overview sets out the landscape.

Mounjaro is a prescription-only medicine. If you would like a clinician to assess whether it suits your situation, start your free consultation with our GPhC-registered prescribers.